WHO: Two monoclonal antibody formulations to treat Ebola

by
WHO: Two monoclonal antibody formulations to treat Ebola

The drugs — Regeneron’s Inmazeb and Ridgeback’s Ebanga (mAb114) — use lab-made monoclonal antibodies that mimic natural antibodies to fight infections.

THE World Health Organisation recommended today the use of two preparations with monoclonal antibodies against him Ebolasaying that the administration of these drugs combined with better care has revolutionized “the treatment of a disease that was once thought to cause almost certain death.”

It is the first time that the WHO has made recommendations for treatments to deal with Ebola.

The drugs — Regeneron’s Inmazeb and Ridgeback’s Ebanga (mAb114) — use lab-made monoclonal antibodies that mimic natural antibodies to fight infections.

“Advances in supportive care and pharmacotherapeutics over the past decade have revolutionized the treatment of Ebola. Ebola virus disease was once thought to cause almost certain death. But that is no longer the case,” said Robert Fowler, a professor at the University of Toronto. of Canada and co-chair of the WHO guideline development group. Effective care and the use of these medications now lead to the recovery of the “vast majority” of people from Ebola, he said, without giving specifics.

The new recommendations follow trials of dengue drugs in the Democratic Republic of Congo during the 2018-2020 outbreak there. Dr. Janet Diaz, head of the clinical management unit of the WHO’s Health Emergencies program, told reporters that the drugs are now available in DR Congo, but more work needs to be done to improve access.

“Access roads are a priority for work right now,” he said.

RES-EMP

You May Also Like

Recommended for you

Immediate Peak